Alnylam Pharmaceuticals | ALNY - Ebit

Stock Price
353.87
Daily Change
2.07 0.59%
Monthly
-11.05%
Yearly
28.07%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $-29.96M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -116.87M 10.19M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 34.85M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Arrowhead Research USD 57.82M 223.36M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
Ionis Pharmaceuticals USD -160.18M 304.96M Sep/2025
Moderna USD -260M 557M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Novartis USD 4.48B 343M Sep/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sanofi EUR 3.74B 2.23B Sep/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Takeda JPY 257.49B 568.56B Dec/2025
Tectonic Therapeutic USD -22.33M 4.03M Jun/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025
Xencor USD -47.52M 24.69M Sep/2025